Worldwide Clinical Trials has just finished buying Catalyst Clinical Research as part of its plan to improve its oncology clinical research capabilities. This merger makes it easier for the company to support complicated cancer drug trials all over the world. As a result, the global organization now has more knowledge in late-stage clinical development and regulatory affairs.
“The acquisition of Catalyst strengthens Worldwide’s capabilities in a very deliberate way, building a stronger, more capable CRO partner for our customers,” said Alistair Macdonald, Chief Executive Officer of Worldwide.“It expands our reach into earlier phase oncology, adds targeted FSP and biometrics capabilities, and accelerates our technology platforms, allowing us to better support customers across the full development lifecycle with greater speed, flexibility, and transparency.”
“The completion of the Catalyst acquisition deepens Worldwide’s oncology offering and global reach,” said Matt Jennings, Executive Chairman of Worldwide and Senior Operating Partner of Kohlberg, the majority owner of the Company. “Catalyst’s expertise, technology, and strong biotech relationships are a natural fit for Worldwide and reinforce our strategy to build a differentiated, technology-enabled CRO.”
“Joining the Worldwide team is an exciting next chapter for Catalyst,” said Nik Morton, former President and CEO of Catalyst, who joins Worldwide as EVP, Chief Strategy & Transformation Officer. “We are energized by the cultural alignment between our teams and share a deep commitment to scientific excellence, operational integrity, and a people-first approach. Together, we are well-positioned to deliver even greater value to customers worldwide.”
Integration Strategy to Drive Growth and Innovation
Also, analysts say that this purchase marks a major change in the world of mid-sized CROs. The team wants to close the gap between early discovery and selling things all over the world. This synergy will definitely make things easier for clinical researchers.
In addition to Morton, Catalyst’s Chairman of the Board, Nick Dyer, joins Worldwide’s Board of Directors. The company has established an integration team and is executing a comprehensive plan to ensure a smooth transition for employees, customers, and partners. The Company will leverage its best strengths and practices to unlock new growth and innovation opportunities for customers.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
